Sign In
Buy GPCR
$48.04
-1.43 (-2.89%)
At Close: Jul 31, 2026
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
04:05pm, Tuesday, 27'th Aug 2024
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry Former Shire CEO brings more than 30 years of experience in building
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
04:05pm, Monday, 26'th Aug 2024
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
12:00pm, Monday, 26'th Aug 2024
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contender
3 Promising Biotech Stocks for the Long-Term: August 2024
02:00pm, Tuesday, 13'th Aug 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
09:56am, Wednesday, 24'th Jul 2024
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
09:20am, Monday, 22'nd Jul 2024
Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
06:08am, Friday, 12'th Jul 2024
There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
10:09am, Friday, 28'th Jun 2024
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. Just look at Eli Lilly (NYSE: LLY ).
Could Structure Therapeutics Become the Next Novo Nordisk?
09:53am, Monday, 17'th Jun 2024
Structure Therapeutics is developing a potentially powerful weight loss medicine. That medicine may end up being more effective than Novo Nordisk's offerings.
Structure Therapeutics CEO on GLP drugs
06:37pm, Tuesday, 11'th Jun 2024
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to discuss the weight loss drug boom and the company's recent data finidngs in its own drug.
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
11:00am, Tuesday, 11'th Jun 2024
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
04:57am, Tuesday, 11'th Jun 2024
Structure Therapeutics is a clinical-stage biotech developing a small-molecule drug that mimics an important gut hormone. Early results for Structure Therapeutics' lead candidate compare well with Weg
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
07:30am, Sunday, 09'th Jun 2024
Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader.
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
07:53pm, Wednesday, 05'th Jun 2024
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
